Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 11;16(Supplement_2):ii30-ii41.
doi: 10.1093/ecco-jcc/jjac011.

Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm

Ferdinando D'Amico  1   2 , Laurent Peyrin-Biroulet  3 , Silvio Danese  2
Affiliations
Review

Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm

Ferdinando D'Amico et al. J Crohns Colitis. .

Abstract

The treatment of patients with moderate to severe Crohn's disease [CD] is still challenging. Therapeutic options include steroids, immunosuppressants, anti-TNFα agents, vedolizumab, and ustekinumab. Ustekinumab is a monoclonal antibody blocking the p40 subunit of IL-12 and IL-23. It showed to be effective and safe in randomised clinical trials and real-life studies and is currently approved for the management of CD patients who are naive to biologics and those who have already been treated with such medications. However, to date, a detailed and approved therapeutic algorithm is not available. The aim of this review is to report the most recent and updated data on the efficacy and safety of ustekinumab for the treatment of patients with moderate to severe CD and to define the optimal management of these patients.

Keywords: Crohn’s disease; Inflammatory bowel diseases; algorithm; ustekinumab.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Proposed algorithm for use of ustekinumab in patients with moderate-severe active Crohn’s disease.
Figure 2:
Figure 2:
Strengths and challenges of ustekinumab use in the treatment of Crohn’s disease.
See this image and copyright information in PMC

References

    1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet 2017;389:1741–55. - PubMed
    1. Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers 2020;6:22. - PubMed
    1. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis 2020;14:4–22. - PubMed
    1. Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010;10:587–604. - PubMed
    1. Johnson & Johnson. Content Lab U.S. FDA Approves STELARA® [Ustekinumab] for Treatment of Adults With Moderately to Severely Active Crohn’s Disease. | https://www.jnj.com/media-center/press-releases/fda-approves-stelara-ust... Accessed September 4, 2021.

Grants and funding